Blood Journal
Leading the way in experimental and clinical research in hematology

A two-step approach to myeloablative haploidentical stem cell transplantation: a phase I/II trial performed with optimized T-cell dosing

  1. Dolores Grosso1,*,
  2. Matthew Carabasi1,
  3. Joanne Filicko-O'Hara1,
  4. Margaret Kasner1,
  5. John L. Wagner1,
  6. Beth Colombe2,
  7. Patricia Cornett Farley3,
  8. William O'Hara4,
  9. Phyllis Flomenberg5,
  10. Maria Werner-Wasik6,
  11. Janet Brunner7,
  12. Bijoyesh Mookerjee1,
  13. Terry Hyslop1,
  14. Mark Weiss1, and
  15. Neal Flomenberg1
  1. 1 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States;
  2. 2 Department of Tissue Typing, Thomas Jefferson University Hospital, Philadelphia, PA, United States;
  3. 3 Stem Cell Processing Laboratory, Thomas Jefferson University Hospital, Philadelphia, PA, United States;
  4. 4 Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA, United States;
  5. 5 Department of Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia, PA, United States;
  6. 6 Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, United States;
  7. 7 Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, United States
  1. * Corresponding author; email: dolores.grosso{at}jefferson.edu
PDF Container